Who LUTATHERA Could Help

LUTATHERA has been shown to help people with NETs in 2 separate clinical trials.

Trial 1: LUTATHERA Was Studied in People Who Had Already Tried Long-Acting Octreotide Alone

This clinical trial studied 229 people with NETs in their midgut. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.

Longer Time Without Disease Progression for Patients Treated With LUTATHERA
People taking LUTATHERA were 79% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone.

^a Tumors shrink by ≥30% from baseline.
^b Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.

Trial 2: LUTATHERA Was Studied in People Who Were Newly Diagnosed With GEP-NETs

This clinical trial studied 226 people with NETs in their GI tract, particularly in the pancreas or small intestine. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.

Longer Time Without Disease Progression for Patients Treated With LUTATHERA
People taking LUTATHERA were 72% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone.

^c Tumors shrink by ≥30% from baseline.
^d Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.

GEP-NETs, gastroenteropancreatic neuroendocrine tumors; GI, gastrointestinal; NETs, neuroendocrine tumors.

Next: Additional Information After Receiving LUTATHERA >